Background. The impact of postoperative complications on the administration of adjuvant therapy following pancreaticoduodenectomy (PD) for adenocarcinoma is still unclear. Methods. A retrospective review of all patients undergoing PD at our institution between 1995 and 2011 was performed. Clinicopathological data, including ClavienDindo complication grade, time to adjuvant therapy (TTA), and survival, were analyzed. Approximately 45,200 cases of pancreatic cancer (PC) are diagnosed yearly in the US, with 38,500-attributable cancer-related deaths.
analysis at Johns Hopkins Hospital (JHH; Baltimore, MD, USA) 12 demonstrate a survival benefit with adjuvant therapy over surgery alone. Additionally, a retrospective analysis of 616 patients undergoing PD for PC who received postoperative adjuvant therapy demonstrated improved median survival (14 vs. 10 months) and 2-year survival (40 vs. 31 %) when compared with observation (p = 0.003). 4 Recently, a collaborative study demonstrated adjuvant therapy was associated with improved survival after PD. 5 Matched-pair analysis demonstrated overall survival (OS) was longer with adjuvant therapy (21.9 vs. 14.3 months median survival; p \ 0.001).
Based on these results, adjuvant therapy is now considered standard treatment following PD for PC. Adjuvant chemotherapy (CT) typically commences within 8-10 weeks of surgical resection. [2] [3] [4] [5] [6] [7] Several studies have demonstrated early initiation of adjuvant CT is associated with improved survival for colorectal [13] [14] [15] [16] [17] and breast cancers. [18] [19] [20] Murakami et al. 3 reported starting adjuvant CT within 20 days of pancreatic resection improves 5-year OS (52 vs. 26 %; p = 0.013) and 5-year disease-free survival (53 vs. 22 %; p = 0.007).
Postoperative complications are common following PD (30-50 %) 4, 7, [21] [22] [23] and we hypothesized that complications delay adjuvant therapy, resulting in adverse long-term outcomes. Postoperative complications appear to be associated with worse long-term outcomes in esophageal, 24, 25 colorectal [26] [27] [28] and PCs. 4, 22, 29 However, the relationship of postoperative complications, time to initiation of adjuvant therapy and long-term survival for PC remains unclear, although some studies have started to explore this issue. 30, 31 This study analyzes the impact of postoperative complications on administration of adjuvant therapy and OS for a large cohort of patients undergoing PD for PC at our institution.
METHODS

Study Design and Participants
This study was approved by the Institutional Review Boards of JHH. We reviewed all patients who underwent PD for pancreatic adenocarcinoma at JHH between 24 January 1995 and 23 February 2011 (n = 1,443). We excluded patients who received neoadjuvant therapy (n = 114), initiated adjuvant therapy more than 6 months after surgery (n = 10), and those missing critical clinical information (n = 175). Clinical and pathologic data were obtained and confirmed by a chart review. Survival was determined by review of clinic notes, cancer center abstracting services, and the Social Security Death Index.
Surgical Procedures
Patients underwent either a pylorus-preserving PD, a classic PD, or a total pancreatectomy. 5 Surgical margins were considered positive if carcinoma was close (within 1 mm) or present at any of the final resection margins. Pathology specimens were reviewed by a single pathologist at JHH (RHH). 32 
Postoperative Complications
A more detailed report of our postoperative complications was described previously. 7 The present definition and clinical grading of postoperative pancreatic fistula (POPF) was according to the International Study Group (ISGPF) criteria. 33 All complications were categorized using the modified Clavien-Dindo classification, 34, 35 which stratifies complications as grades 0-V. Complications of grade IIIb or more were regarded as severe. For patients with more than one complication, the highest grade was used for analysis.
Postoperative Adjuvant Therapy
Patients are routinely referred to a medical and radiation oncologist following PD for adenocarcinoma at JHH. Patients were encouraged to accept single-modality adjuvant CT, radiation therapy (RT), or both CT and RT. 4, 21 CT regimens were either gemcitabine-based (alone or combined with paclitaxel) or 5-fluorouracil (FU) based (5-FU/ leucovorin combined with oxaliplatin or irinotecan). For patients receiving RT, adjuvant external-beam RT was delivered with linear accelerators using multiple-field techniques, with the median RT dose of 50.4 Gy and daily fraction of 1.8 Gy.
Time to adjuvant therapy (TTA) was defined as the interval between the date of surgery and first adjuvant therapy treatment.
Statistical Analysis
Variables included in analyses were age, sex, length of stay (LOS), operative time, estimated blood loss (EBL), T stage, N stage, and complication grade. Categorical variables between groups were compared using the Chisquared test or Fisher's exact test, of which factors found to be significant on univariate analysis were subjected to multivariate analysis using a logistic regression model. OS and TTA were analyzed as survival data. The survival curves were constructed using the Kaplan-Meier method, 36 and comparisons of OS or TTA between groups were made using the log-rank test or together with the Breslow test. OS (in months) with 95 % confidence intervals (CI) was estimated within each group. The proportion of individuals surviving 2, 5, and 10 years was calculated using life tables. Factors found to be significant on univariate analysis were subjected to multivariate analysis using a Cox proportional hazards model. 37 All statistical analyses were performed using Statistical Package for the Social Sciences, version 16.0 (SPSS, Chicago, IL, USA).
RESULTS
Patient Demographics and Clinicopathological Characteristics
The 1,144 eligible patients included 600 (52.4 %) men and 544 (47.6 %) women, with a median age of 68 years (range 31-93 years). The median operative time was 380 min (range 230-792 min), with a median EBL of 700 ml (range 50-15,000 ml). Postoperative complications occurred in 562 patients (49.1 %), of which the leading three complication grades were II (n = 199, 17.4 %), IIIa (n = 171, 14.9 %) and I (n = 144, 12.6 %). 48 patients (4.2 %) experienced a severe complication (grade C IIIb). 523 patients (45.7 %) received surgery alone, 472 (41.3 %) received multimodality adjuvant therapy, and 149 (13.0 %) received single-modality adjuvant CT (n = 126, 11.0 %) or RT (n = 23, 2.0 %). Among those patients who received CT (n = 598), 334 patients received single-agent CT, 186 patients received multi-agent CT, and 78 patients were unknown. Among 230 patients (38.5 %) receiving CT at JHH, seven patients did not finish CT due to toxicity or mortality, and eight patients switched CT regimen or agents for disease progression and metastasis. Of patients receiving RT (n = 495), 146 patients (29.5 %) received RT at JHH. The most common pathologic T stage was T3 (n = 819, 71.6 %), followed by T2 (n = 248, 21.7 %). Only 63 patients (5.5 %) underwent pancreatectomy with vascular resection and reconstruction. 912 patients (79.7 %) had lymph node metastasis, which included 788 with N1 (68.9 %) and 124 with N2 (10.8 %). LOS ranged from 4 to 374 days, with a median LOS of 9 days. 72 patients (6.3 %) had POPF, including 38 grade B (3.3 %) and 11 grade C (1.0 %) ( Table 1) .
Comparison of Clinicopathological Factors According to Adjuvant Therapy
Of the 1,144 patients, only 621 (54.3 %) received adjuvant therapy, and 523 (45.7 %) received none. Clinicopathological characteristics of the two groups are shown in Table 2 . There were no significant differences in sex, operative time, EBL, postoperative complication rate, T stage, or N stage between the two groups. However, age [ 68 years [odds ratio (OR) 0.457; p \ 0.001] and LOS [ 9 days (OR 0.685; p = 0.002) was associated with a decreased likelihood of receiving adjuvant therapy. Multivariate analysis using a linear regression model demonstrated that both age [ 68 years and 
Comparison of Clinicopathological Factors According to Postoperative Complication
Postoperative complications occurred in 562 (49.1 %) patients. Clinicopathological characteristics stratified according to postoperative complications are shown in Table 2 . There were no significant differences in EBL and N stage between the patients with and without postoperative complications. On univariate analysis, factors associated with postoperative complications included higher T stage (p = 0.017), male sex (OR 1.367; p \ 0.001), age [ 68 -years (OR 1.418; p \ 0.001), operative time [ 380 min (OR 1.633; p \ 0.001), and LOS [ 9 days (p = 0.002). Multivariate analysis revealed male sex, age [ 68 years, operative time [ 380 min, and T stage were each independent predictors of postoperative complications after PD for PC (Table 2) .
Association between Postoperative Complications and Adjuvant Therapy Receipt
Postoperative complications occurred in 49.1 % of patients, of which one-eighth were severe complications (grade CIIIb). Complication grade (0-V), postoperative Postoperative a Univariate analysis of categorical variables between the two groups was performed using the Chi-squared test b Significant factors were then subjected to multivariate analysis using a logistic regression model PD pancreaticoduodenectomy, EBL estimated blood loss, LOS length of stay, CI confidence interval, OR odds ratio complication0.471 No260322 Yes263299 a Univariate analysis of categorical variables between the two groups was performed using the Chi-squared test b Significant factors were then subjected to multivariate analysis using a logistic regression model complication (yes or no) and severe complications (CIIIb) were compared (Table 3 ). There was no relationship between the occurrence of any complication and administration of adjuvant therapy. However, higher-grade complications (p = 0.001) and severe complications (p \ 0.001) were significantly associated with not receiving adjuvant therapy. In a subgroup of patients receiving adjuvant therapy, associations between the presence of a postoperative complication, grade of postoperative complication, severe complication, and adjuvant therapy modality were also investigated. Single-modality CT or RT was associated with both the presence (p \ 0.001) and grade (p = 0.001) of postoperative complication. More patients with postoperative complications received singlemodality CT or RT (31.4 %) than patients without complications (17.1 %; p \ 0.001).
Comparison of Clinicopathological Factors According to Time to Adjuvant Therapy
The overall median TTA for the 621 patients who received adjuvant therapy was 60 days. TTA survival curves were constructed using the Kaplan-Meier method, 36 and univariate analysis of TTA between groups were made using the Breslow test. The presence of a postoperative complication significantly delayed the median TTA (p = 0.002). All other factors, including complication grade and severe complications (CIIIb), did not correlate with TTA.
Survival and Prognostic Factors
The estimated OS rates of all 1,144 patients undergoing PD for PC were 37.2 % at 2 years, 14.8 % at 5 years, and 10.2 % at 10 years. Median OS was 18.1 months (95 % CI 16.9-19.4 months). The prognostic impact of complications and adjuvant therapy were investigated by evaluating clinicopathological factors associated with OS using univariate analyses and multivariate analyses (Table 4) Categorical variables between the two groups were compared using the Chi-squared test or Fisher's exact test PD pancreaticoduodenectomy, CT chemotherapy, RT radiation therapy Nevertheless, patients without complications who received adjuvant therapy had longer survival compared with patients who did not receive adjuvant therapy (22.5 vs. 15.7 months; p = 0.013), and compared with patients who experienced a complication and received no adjuvant therapy (22.5 vs. 10.7 months; p \ 0.001). Patients with complications who received no adjuvant therapy had shorter survival than those who received adjuvant therapy (10.7 vs. 20.4 months; p \ 0.001), and those without complications who received no adjuvant therapy (10.7 vs. 15.7 months; p \ 0.001) (Fig.1) .
DISCUSSION
Receiving adjuvant therapy is associated with improved survival and is typically recommended after resection of PC. 4, 5, [9] [10] [11] [12] 38 Early initiation of adjuvant CT appears to have a survival benefit for some cancer types. [13] [14] [15] [16] [17] [18] [19] [20] including PC. 3 Postoperative complications have been associated with worse long-term outcomes in esophageal cancer, 24, 25 colorectal cancer, [26] [27] [28] and PC. 4, 22, 29 However, the relationship between postoperative complications following PD for PC and receipt of adjuvant therapy is unclear.
In this large cohort of patients following PD, only 54.3 % of patients received adjuvant therapy. The large proportion of patients (45.7 %) who do not receive adjuvant CT is similar to other reports. 4 suggested that slow recovery from surgery and postsurgical complications might influence whether a patient receives adjuvant therapy following colorectal resections. We attempted to identify reasons for patients not receiving adjuvant therapy. Univariate and multivariate analysis found age [ 68 years (p \ 0.001) and LOS [ 9 days (p = 0.002) were associated with a lower likelihood of receiving adjuvant therapy, suggesting that old age and slow recovery were major obstacles. Since age C 75 years was found to be a risk factor for early mortality following PD, 39 it is also possible that adjuvant recommendations were less aggressive for elderly patients.
Interestingly, although the presence of a complication correlated with delays in TTA, the grade and severity of complication did not. However, the Clavien-Dindo grade of complication (p = 0.001), and particularly more severe complications (CIIIb) (p \ 0.001), significantly correlated to no adjuvant therapy being administered. Additionally, even when patients with postoperative complications did receive adjuvant therapy, single-modality adjuvant therapy (p = 0.001) was more frequently chosen. This is important because no adjuvant therapy and use of CT or RT alone correlated with worse OS.
The overall median TTA in the 621 patients who received adjuvant therapy was 60 days, which is somewhat longer than we expected. In comparison, the median TTA was 46 days for CT and 61 days for CRT in the ESPAC-1 trial, 9 36 days in the CONKO-001 trial, 11 and 55 days in the ESPAC-3 trial. 10 It is possible that the nature of these protocol-driven randomized trials impacted the TTA compared with our retrospective review.
Several studies have investigated the impact of postoperative complications on long-term survival in PC, 3, 4, 22, 29 but only two have focused on TTA.
3, 29 Murakami et al. 3 reported median TTA for 104 patients was only 20 days and only postoperative complications related to longer TTA. However, this study only included patients who actually received adjuvant therapy and TTA was categorized as B20 days or[20 days. Petermann et al. 29 reported delayed TTA for patients with severe postoperative complications from PD (82 vs. 55 days), but grade V complications were excluded, only 96 patients were evaluated, and less than half actually received adjuvant therapy.
We evaluated detailed TTA data and compared TTA amongst groups based on clinicopathological factors. Postoperative complications significantly delayed median TTA (62 vs. 55 days; p = 0.002), but 7 days is of questionable clinical significance. For patients receiving adjuvant therapy, TTA was not associated with improved survival. Interestingly, neither complication grade nor severe complications (CIIIb) correlated with TTA, possibly due to the small number of grade IV and V complications.
Similar to other studies, 3, 4, 22 we demonstrated that patients without a complication had a longer OS (19.5 vs. 16.1 months; p \ 0.001), particularly for patients who received no adjuvant therapy (15.7 vs. 10.7 months; p \ 0.001). The impact of postoperative complications on survival was not statistically significant for patients who received adjuvant therapy (20.4 vs. 22.5 months; p [ 0.05). On the other hand, patients who received no adjuvant therapy had a significantly worse survival regardless of whether they had a complication (p \ 0.001) or not (p = 0.013).
CONCLUSIONS
Complications and no administration of adjuvant therapy are common (49.1 % and 45.7 %, respectively) following PD for PC. Although the presence of complications does not appear to impact whether adjuvant therapy is administered, the TTA is longer and use of single-modality adjuvant therapy is more common. Higher-grade complications result in significantly higher rates of no adjuvant therapy administration. Complications and lack of multimodality adjuvant therapy correlate to worse OS following PD for PC. Identifying patients at increased risk for complications and those unlikely to receive CRT warrants further investigation as they may benefit from a neoadjuvant approach.
